Jabbour, E., Morris, V., Kantarjian, H., Yin, C. C., Burton, E., & Cortes, J. (2012). Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. American Society of Hematology.

Jabbour, Elias, Van Morris, Hagop Kantarjian, Cameron C. Yin, Elizabeth Burton, i Jorge Cortes. Characteristics and Outcomes of Patients With V299L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2012.

Jabbour, Elias, et al. Characteristics and Outcomes of Patients With V299L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2012.